^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABP 206 (nivolumab biosimilar)

    i
    Other names: ABP 206, ABP-206, ABP206
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3d
    NRG-BN007: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (clinicaltrials.gov)
    P2/3, N=159, Completed, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH1 R132
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • ABP 206 (nivolumab biosimilar)
    3d
    NRG-HN005: De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2/3, N=384, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Opdivo (nivolumab) • cisplatin • ABP 206 (nivolumab biosimilar)
    3d
    Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    3d
    Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov)
    P2/3, N=427, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • paclitaxel • ABP 206 (nivolumab biosimilar)
    4d
    Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (clinicaltrials.gov)
    P3, N=1175, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jan 2028 | Trial primary completion date: Sep 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
    4d
    A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    7d
    A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma (clinicaltrials.gov)
    P3, N=256, Completed, Amgen | Trial primary completion date: Oct 2025 --> Mar 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
    7d
    Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Aug 2028 | Trial primary completion date: Jun 2027 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    12d
    Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (clinicaltrials.gov)
    P1, N=66, Suspended, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Sep 2028 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Sep 2028
    Trial completion date • Trial suspension • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ZEN-3694 • ABP 206 (nivolumab biosimilar)
    22d
    Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov)
    P2, N=20, Recruiting, Emory University | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • ABP 206 (nivolumab biosimilar)
    24d
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov)
    P2, N=314, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    28d
    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | N=18 --> 8 | Trial completion date: Nov 2025 --> Feb 2027
    Enrollment change • Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)